MIGENIX Board Changes (Hepatitis C Infection)

MIGENIX Board Changes
[Press Release] CNW Group via Yahoo! Finance - Jan 09 2:17 PM
MIGENIX Inc. , a clinical-stage developer of drugs for infectious and degenerative diseases, today announced that Michael Abrams, Ph.D., has retired from its Board. This change reduces the size of the Board to eight directors from nine.Save to My Web

InterMune Completes Divestiture of Infergen(R) for Up to $135.5 Million in Cash
RedNova - Jan 03 7:33 AM
BRISBANE, Calif., Jan. 3 /PRNewswire-FirstCall/ -- InterMune, Inc.Save to My Web

Older Hepatitis C Patients Prove Difficult to Treat
RedNova - Jan 06 7:47 PM
Combination therapy in older hepatitis C patients results in more adverse effects necessitating discontinuation of treatment, lowering of dosages, and lower long-term benefits, according to a recent study carried out in Japan.Save to My Web

Diazyme test kit given green light
San Diego Daily Transcript via Yahoo! News - Dec 22 11:54 AM
Diazyme Laboratories (News) announced Thursday that the U.S. Food and Drug Administration has granted the San Diego biotech company 510(k) clearance to market its Enzymatic Total Bile Acids Assay Kit for the quantitative determination of total bile acids in human blood samples.Save to My Web

Anadys Pharmaceuticals to Present at the 24th Annual JP Morgan Healthcare Conference
[Press Release] PR Newswire via Yahoo! Finance - Jan 05 6:00 AM
Anadys Pharmaceuticals, Inc. announced today that it will present at the 24th Annual JP Morgan Healthcare Conference on Thursday, January 12, 2006 at 9:00 a.m. PST at the Westin St.Save to My Web